Login
$PYXS
$1.43 +$0.02 (1.34%) After hours

Company Executives

Officer Age In this role 2025 pay Source
Thomas Civik Also a director
Chief Executive Officer
Title from the Form 8-K dated Sep 4, 2026
57 Not stated Not reported
Jitendra Wadhane
Principal Financial and Accounting Officer
45 Since 2025
1 year
$766,752

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Board of Directors

From the proxy statement filed Apr 30, 2026 · updated by the 8-K of Sep 8, 2026

Directors
7
serving now
Independent
5 of 7
stated in the proxy
Average tenure
4.0 years
from year joined
CEO also chairs the board
Yes
Thomas Civik and John Flavin
Director On board Independent Committees Other public boards 2025 pay Source
Thomas Civik
2021
5 years
Not independent None stated None stated $75,904
John Flavin
Not stated Independent
Audit Committee · Chair Compensation Committee · Chair
Syntax Bio, Inc. $155,904
Freda Lewis-Hall
2021
5 years
Independent None stated CDT Equity (formerly, Conduit Pharmaceuticals) $73,404
Michael A. Metzger
2024
2 years
Independent
Audit Committee
Syndax Pharmaceuticals Inc. $118,404
Jakob Dupont
2023
3 years
Not independent None stated Avenzo, Bolt Biotherapeutics $196,654
Darren Cline
2021
5 years
Independent
Audit Committee
Pliant Therapeutics $83,404
Rachel Humphrey
2022
4 years
Independent None stated Voro Therapeutics $207,529

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

3 disclosed in the proxy filed Apr 30, 2026
Pfizer Inc.
A combined $25.0 million
December 2020

Pfizer License Agreement: upfront cash payment and issuance of Series B convertible preferred stock to Pfizer, with future contingent payments and royalties

Pfizer Inc.
Amount not stated
2022 to 2023

Amended and Restated License Agreement with Pfizer: issuance of common stock and a cash payment to Pfizer

University of Chicago
Less than $0.1 million
years ended December 31, 2025 and 2024

University License Agreement and sponsored research agreement; company issued shares and owes milestones, royalties and sublicensing payments

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support